Rocket Lab Stock Sold Off While Its Operating Margin Kept Climbing

Cash burn and a softer gross-margin guide have added to a slide that leaves the stock well below its high, yet its operating loss per dollar of revenue has narrowed in each of the last three years.

Rocket Lab (RKLB) trades at $80.01, roughly 53% of its 52-week high, after a 31.8% slide over the past three months. The selling has a focus: cash burn and, most recently, a softer gross-margin guide for the third quarter of 2026. Underneath that sits a number the drawdown gives little credit for: the operating margin, which has improved in each of the last three years.

From 69 Cents Of Operating Loss Per Revenue Dollar To 29 Cents

Three years ago Rocket Lab lost 69 cents at the operating line on every dollar of revenue. That became 53 cents, then 44 cents, and 29 cents over the last twelve months, on revenue of $0.8 billion that grew by more than half. That is roughly forty points of the gap to operating breakeven closed in three years, with no year going backwards.

The Rocket Company Is Now Mostly A Satellite Company

Space Systems delivered $189.5 million of the record $234 million of Q2 2026 revenue, and GAAP gross margin came in at 36.1%, above the 33% to 35% the company had guided, even with a mix shift toward the slightly lower-margin satellite platforms business and the newly acquired Mynaric. Management guided GAAP gross margin down to 29% to 31% for Q3 2026 on a shift in mix within its Space Systems business, though it expects a beneficial remixing impact on gross margins beyond Q3 2026. The pending $8 billion Iridium acquisition—which management expects to complete in mid-2027 using the recent $1.08 billion share sale alongside additional financing—would more than double the company’s revenue while adding a third vertical in space applications.

Does A Climbing Margin Answer A $110 Million Quarterly Burn?

Only partly. Non-GAAP free cash flow was a use of $110.1 million in Q2 2026 against $77.4 million in Q1 2026, and management expects the burn to stay elevated in Q3 2026 while Neutron development and production run. Improving margins do not stop that spending; they shorten the distance still to cover.

Roughly $2.4 billion of cash, cash equivalents, restricted cash, and marketable securities sat on the balance sheet at the end of Q2 2026, but with $1.08 billion of that balance—raised through a now-terminated at-the-market share program—earmarked to help fund the pending $8 billion Iridium acquisition, the remaining liquidity covers roughly twelve times that quarter’s cash use. A company that has had to fund itself that way is a different proposition from the established cash generators in the Trefis High Quality Portfolio.

The Operating Line Matters As Much As The Neutron Countdown

None of this makes the stock cheap: it trades at about 65 times trailing sales and is up 79% over the past 12 months, so the fall has unwound a run rather than marked a broken business. The case is narrower than cheapness. With $2.36 billion of backlog at the end of Q2 2026 the demand is contracted, and the open question is the margin earned on it, where three straight years of improvement at the operating line are the evidence. What settles it is whether the operating line keeps closing that gap once the guided Q3 2026 gross-margin dip passes, and that matters as much as the date Neutron first flies. Whether a fall this size is worth stepping into is the question behind our screen of which beaten-down names have the fundamentals to justify buying the fall.

Betting On A Margin Curve Is Still Betting On One Curve

The case rests on one line continuing to bend as it has for three years, and a single holding carries the whole outcome if it does not. A rules-based basket such as the Trefis High Quality Portfolio is the usual answer to risk shaped like that. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.